New drug combo shows promise for tough head and neck cancers
NCT ID NCT07254585
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tests a combination of two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has come back or spread. The goal is to see if the treatment can shrink tumors and control the disease. About 70 adults aged 18-75 who have not had prior systemic therapy for advanced disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital Affiliated To Tongji University
RECRUITINGShanghai, Shanghai Municipality, 100176, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.